

R1 R2 R3 PG0 PG1 Estagiário Tecnólogo
PIBIC Last Name - Ballalai First Name - Priscilla Middle - Luppi

Service (sector) Tumor and Pathology N° CEP

TOPICAL MITOMYCIN C (MMC) 0.02% IN THE TREATMENT OF CORNEAL - CONJUNCTIVAL INTRAEPITHELIAL NEOPLASIA (CCIN): LONG-TERM RESULTS.

BALLALAI, PL; ERWENNE, CM; RIGUEIRO, M; MARTINS, MC

PURPOSE: To evaluate the efficacy and the long-term effects on the ocular surface with the use of topical MMC 0.02% in the treatment of CCIN. **METHODS:** Patients with clinical and cytological diagnosis of CCIN were included. They were divided into two groups: Group 1: primary lesion; Group 2: recurrent lesion. MMC 0.02% qid for 28 days was given to all patients. Ophthalmological exams were performed weekly during the first month, monthly during the first three months, every three months during the next two years, and every six months thereafter. Effectiveness of the treatment and side effects were recorded. **RESULTS:** Fourteen patients were enrolled, 9 in group 1 and 5 in group 2. Cytology was negative in all patients one month after the end of treatment. The mean follow up was 42.2 months (range, 12 to 64 mo.). Recurrence rate was 11.1% in group 1 and 40% in group 2, and occurred after three months in two patients (one of group 1, and one of group 2), and after 24 months in one patient of group 2. Epithelial defect rate was 11.1% patients of group 1 and 40% in group 2 (Group 1: 1 patient; Group 2: 2 patients) with a mean of 16.6 months (range, 12 – 24 months). **CONCLUSIONS:** Topical MMC 0.02% is effective in the treatment of CCIN. Patients with recurrent lesions are at higher risk of developing recurrences, as well as developing epithelial defects.